Adherence to Long-Term Therapies - Evidence for Action
(2003; 211 pages) View the PDF document
Table of Contents
View the documentPreface
View the documentAcknowledgements
View the documentScientific writers
View the documentIntroduction
View the documentTake-home messages
Open this folder and view contentsSection I - Setting the scene
Open this folder and view contentsSection II - Improving adherence rates: guidance for countries
Close this folderSection III - Disease-Specific Reviews
Open this folder and view contentsChapter VII - Asthma
Open this folder and view contentsChapter VIII - Cancer (Palliative care)
Open this folder and view contentsChapter IX - Depression
Open this folder and view contentsChapter X - Diabetes
Open this folder and view contentsChapter XI - Epilepsy
Open this folder and view contentsChapter XII - Human immunodeficiency virus and acquired immunodeficiency syndrome
Close this folderChapter XIII - Hypertension
View the document1. Prevalence of adherence to pharmacotherapy in patients with hypertension
View the document2. Impact of adherence on blood pressure control and cardiovascular outcome
View the document3. Adherence to non-pharmacological treatment
View the document4. Factors contributing to adherence
View the document5. Interventions for improving adherence
View the document6. Conclusions
View the document7. References
Open this folder and view contentsChapter XIV - Tobacco smoking cessation
Open this folder and view contentsChapter XV - Tuberculosis
Open this folder and view contentsAnnexes
Open this folder and view contentsWhere to find a copy of this book

6. Conclusions

Patients need advice, support and information from health professionals in order to be able to understand the importance of maintaining blood pressure control during the day, to use their drugs rationally, to learn how to deal with missed doses and how to identify adverse events and what to do when they occur. Sharing this responsibility with health professionals is a must - the patient does not need to cope alone.

There is a direct need for research to fill gaps in knowledge on adherence. In general such research should aim at gaining a better understanding of the determinants of adherence discussed above so that effective interventions that address barriers can be developed.

In addition, research should focus on the following important areas:

- validation and standardization of various measures of adherence to prescribed drug therapy and non-pharmacological therapy for hypertension;

- development of valid and reliable questionnaires to obtain information on determinants of adherence;

- investigation of health-related quality-of-life indicators related to patients' adherence to antihypertensive therapy;

- identification of predictors of adherence to pharmacological and non-pharmacological therapy;

- determination of the factors related to behaviour that influence adherence to antihypertensive therapy, such as patient preferences and patient beliefs;

- identifying common risk factors for nonadherence in patients with hypertension, in both developing and developed countries, to study strategies for improving patient adherence;

- understanding of behaviour change principles and mechanisms that promote adherence;

- development of interventions to promote adherence to antihypertensive medication;

- development of materials to involve patients more in managing and regulating their adherence and therefore their hypertension; and

- determination of the reductions in costs and hypertension-related complications resulting from adherence to antihypertensive therapy - issues that are relevant to the needs of patients, managed care organizations and governments.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017